Abiopharma

🔍 Allan Jonathan (Executive)

Company: Stoke Therapeutics, Inc. (STOK)

Report Date: 2025-08-29

Detailed Transactions and Holdings:

• Acquired 850 shares of Common Stock at $7.07 per share (Direct)
  Date: 2025-08-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 24,798.00 | transaction_form_type: 4
• Sold 850 shares of Common Stock at $20.0 per share (Direct)
  Date: 2025-08-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 23,948.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 9,150 shares of Common Stock at $7.07 per share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 33,098.00 | transaction_form_type: 4
• Sold 14,922 shares of Common Stock at $20.1375 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 18,176.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 6,345 shares of Common Stock at $20.0657 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 11,831.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 850 shares of Stock Option (Right to Buy) at $7.07 per share (Derivative)
  Date: 2025-08-29 | Code: M | Expires: 2032-12-06 | equity_swap_involved: 0 | shares_owned_after: 24,951.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 9,150 shares of Stock Option (Right to Buy) at $7.07 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2032-12-06 | equity_swap_involved: 0 | shares_owned_after: 15,801.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.20, inclusive.
• F4: The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.